<DOC>
	<DOCNO>NCT02839798</DOCNO>
	<brief_summary>This study design evaluate safety preliminary efficacy synchronize transcranial magnetic stimulation ( sTMS ) use NeoSync EEG Synchronized TMS device ( NEST ) subject Bipolar Disorder type I Major Depressive Episode . This open label study subject receive treatment 5 day per week 6 week .</brief_summary>
	<brief_title>NeoSync TMS Treatment Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion qualify enrollment study : 1 . 18 70 year age ; 2 . DSM5 primary diagnosis Bipolar Disorder type 1 ( document past manic episode ) , currently Major Depressive Episode diagnostic criterion elicit structured clinical interview ( SCID5RV ) ; 3 . MADRS score ≥ 20 ; 4 . Duration current episode &gt; 4 week 5 . YMRS score ≤ 12 ; 6. baseline EEG sufficient quality quantitative analysis processing ; 7. willing able adhere intensive treatment schedule require study visit ; 8. currently adequate dose mood stabilizer significant evidence base FDA approval antimanic maintenance therapy bipolar disorder ( e.g , valproic acid/divalproex , carbamazepine , lithium , aripiprazole , ziprasidone , risperidone , quetiapine , olanzapine , asenapine , haloperidol , chlorpromazine , paliperidone , cariprazine ) . Subjects exclude study participation one follow exclusion criterion applies : 1. unable unwilling give inform consent ; 2. diagnose current primary psychotic disorder ( rather BD ) ; 3. diagnose current mania hypomanic mood episode ; 4. history moderate severe substance use disorder within past 6 month ( except nicotine caffeine ) ; 5. currently treat stimulant ; 6. clinically defined major neurological disorder ; include , limited , seizure disorder history loss consciousness due head injury great 10 minute , document evidence brain injury ; 7. increase risk seizure reason , include diagnosis increase intracranial pressure , comorbid neurological disorder , use certain medication , highly unstable use alcohol benzodiazepine ; 8. initiation new antidepressant treatment ( new medication , new devicebased stimulation , new psychotherapy ) within 6 week prior study baseline ; 9. active suicidal intent plan detect screening assessment , Investigator 's opinion , likely attempt suicide within next six month ; 10. presence implant cardiac pacemaker , implanted medication pump , intracardiac line ; 11. intracranial implant ( e.g. , aneurysm clip , shunt , stimulators , cochlear implant , stent , electrode ) metal object within near head ( exclude mouth ) , safely remove ; 12. clinically significant unstable medical condition ; 13. female : pregnant , use medically acceptable mean birth control , currently breastfeed ; 14. condition , judgment Investigator could prevent subject completion study ; 15. participant MRI study : ferromagnetic metal implant contraindication image 3 Tesla MRI ; 16. past treatment TMS therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>sTMS</keyword>
	<keyword>NEST</keyword>
	<keyword>NeoSync</keyword>
	<keyword>synchronous</keyword>
	<keyword>non-invasive neuromodulation</keyword>
	<keyword>TMS</keyword>
	<keyword>transcranial magnetic stimulation</keyword>
	<keyword>EEG</keyword>
	<keyword>bipolar</keyword>
	<keyword>depression</keyword>
</DOC>